Navigation Links
Two designer drugs hit same lung cancer target, but only one is effective

Two designer cancer drugs differed dramatically in a laboratory test comparing their ability to shut down a mutant, overactive growth signal in lung cancer cells, reports a team headed by scientists at the Dana-Farber Cancer Institute.

Although both drugs killed cells containing a normal but overactive EGFR (epidermal growth factor receptor) molecule, only gefitinib (Iressa) killed lung cancer cells containing a mutated EGFR molecule. The monoclonal antibody drug cetuximab (Erbitux) had little effect on the mutant signal, evidently because it strikes at a different part of the EGFR molecule.

Reporting in the Aug. 17 issue of the Journal of the National Cancer Institute, the researchers say that the divergent results add to growing evidence that mutations in the targets of designer drugs critically influence their effectiveness. Erbitux is an effective inhibitor of EGFR signals in colorectal cancer, which involves a normal, not mutant, EGFR molecule.

"We now know of several groups of patients who benefit from therapy targeted at EGFR," says Pasi A. Janne, MD, PhD, of Dana-Farber, and a senior author of the paper. "Those with EGFR mutations will benefit from Iressa or Tarceva (erlotinib), while another group, without EGFR mutations, will benefit from Erbitux."

The lead author is Toru Mukohara, MD, and the senior authors are Bruce E. Johnson, MD, and Jänne, all of Dana-Farber.

Iressa and Erbitux both are designed to squelch the overexpressed, or overactive, EGFR signal that spurs growth in several types of cancer. In some forms of the disease, including lung cancer of the non-small-cell type, and colorectal cancer, the abnormal signals are generated by a normal EGFR molecule. In a small percentage of patients with non-small-cell lung cancer (NSCLC), the overactivity stems from a mutant EGFR protein: those patients tend to have a better outlook, and Iressa and Tarceva are particularly effective for them.

Mukohara and his co
'"/>

Source:Dana-Farber Cancer Institute


Page: 1 2

Related biology news :

1. Mouse with designer liver has enhanced glucose tolerance, insulin response
2. Molecular machine may lead to new drugs to combat human diseases
3. Researchers identify target for cancer drugs
4. MetaChip provides quick, efficient toxicity screening of potential drugs
5. Newly discovered pathway might help in design of cancer drugs
6. UNC launches study of liver injury caused by drugs
7. Findings have implications for tracking disease, drugs at the molecular level
8. Future diabetes drugs may target new protein interaction
9. UCLA study assesses cost-effectiveness of Hepatitis B drugs
10. Sponges as drugs
11. Newest HIV drugs should be used with FUZEON(R)

Post Your Comments:
(Date:11/24/2009)... and flabby arteries from collapsing have been tru...are no longer needed -- once the arteries are stre...tors had no choice but to leave them in place. , ...epartment of Biomedical Engineering has developed ...rugs where they,re needed, then dissolves. , "Ou...
(Date:11/24/2009)...od is a matter of debate. A high-profile study a f...cent of their carbon from trees and leaves, eviden...nd aquatic ecosystems. , But new research from t...ly to be true. Algae provide a much richer diet fo...ch published this week in the Proceedings of the ...
(Date:11/23/2009)...ember 23, 2009 Applied mathematicians dissected t...lia ), a characteristic long leaf with a saddle-li... the edges. The simple cause of the lily,s fan-lik...uring differential growthwas revealed by using an ... , Haiyi Liang, a postdoctoral student at Harvar...
Breaking Biology News(10 mins):A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3The cause behind the characteristic shape of a long leaf revealed 2Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan 14511 1Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan 14511 2Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan 14511 3Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan 14511 4Do Women Have a Right to a Breastpump That Works 3F Asks Hygeia 5535 1Do Women Have a Right to a Breastpump That Works 3F Asks Hygeia 5535 2Be overweight and live longer 59643 1
...nt patients with hepatitis C virus (HCV) achieved ... taking the immunosuppressive agent Cyclosporine a.... Cyclosporine also showed efficacy against Hepati... appear in the January 2006 issue of Liver Transpl...ociation for the Study of Liver Diseases (AASLD) a...
...amond, Country Value and Professional brand dog fo... aflatoxins, they have caused at least 100 dog dea...narians, who are growing increasingly alarmed. Som...ibly in more than two dozen other countries remain...y continue to give dogs food containing a lethal t...
...ine Program of the Census of Marine Life, with the...w Brunswick, announced today the first count of kn...more than 50% larger than previous estimates. , ...round species and those that migrate to the region...he international Census of Marine Life. The count ...
Other Biology News:Cyclosporine inhibits hepatitis C virus in vitro 2Dogs keep dying: Many owners unaware of toxic dog food 2Dogs keep dying: Many owners unaware of toxic dog food 3Dogs keep dying: Many owners unaware of toxic dog food 4The diversity of marine life in the Gulf of Maine region is much greater than previously thought 2The diversity of marine life in the Gulf of Maine region is much greater than previously thought 3The diversity of marine life in the Gulf of Maine region is much greater than previously thought 4The diversity of marine life in the Gulf of Maine region is much greater than previously thought 5
(Date:11/25/2009)...wswire-Asia/ -- Sinovac Biotech Ltd. ( SVA),a lea... today that it executed,a joint venture (JV) agree...ogy Co., Ltd. (Sinovac Dalian). The JV will resear...accines. Sinovac will contribute its expertise,and...d-class vaccines; the,other party will bring its l...
(Date:11/24/2009)...FirstCall/ -- IES (Nasdaq: IESC ), a leading nati...tems and services for the commercial, industrial a...ommercial business group has been awarded a contra...cal systems for the Level 4 bio-safety lab (BSL-4)...earch Institute of Infectious Diseases (USAMRIID) ...
(Date:11/24/2009)...v. 24 Dow AgroSciences C...f Hyland Seeds, a division of Thompsons Limited of...ill further expand Dow AgroSciences, current seeds...ion of SmartStax(TM) in 2010 and Dow AgroSci...in 2012. The transactional close is expected in th...
(Date:11/24/2009)...nd, November 24 deCODE,g...approval of all of its,"first day" motions by the ...,(the "Bankruptcy Court"). deCODE last week filed ...f the United States Bankruptcy Code with the,Bankr...ankruptcy Court allow the company to continue,to o...
Breaking Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3
...Webcast and Conference Call Scheduled for Thursday... ET, TUCSON, Ariz., May 13 ImaRx Therapeutics,...pany has postponed its live,webcast and conference...o,discuss first quarter 2008 financial results; th...13, 2008, at 5:00 p.m. ET., The live webcast can ...
...AM, Mass., May 13 Interleukin Genetics,Inc. (Amex...ef Executive,Officer, will present at the Rodman a... on Monday May 19, 2008, at 10:00 a.m. CEST (4:00 ...ien Beach Plaza Hotel, Monte,Carlo, Monaco., A li...able on the,Investors section of the Company,s web...
...EHEM, Pa., May 13 Particle Sciences has expanded,...q ft Class 1000 (ISO 6),clean room. The space also.... The space was added to the existing 15,000 sq ft...linical trial material manufacturing,especially th...is,investment is the latest in a series of acquisi...
Other Biology Technology:Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
RLF (R506-05) from European Collection of Cell Cultures (ECACC)
...Precision Model 440 incorporates four channels of ...friendly easy-to-use instrument. Each channel cons... Bessel lowpass filter, a highpass filter, a line ...l knob sets the amplifier parameters and the value...
Mouse Anti-Xenopus laevis Xenopus nuclear factor, xnf7 Antibody, Unconjugated from Developmental Studies Hybridoma Bank
Rabbit Anti-Human sPLA2-XII Polyclonal Antibody, Unconjugated from BioVendor Laboratory Medicine, Inc.
Biology Products: